Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development
- 13 November 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 12 (12) , 1497-1507
Abstract
Despite the progress in antipsychotic therapy for schizophrenia, the effects are still not satisfactory. There is a high percentage of therapy-resistant patients and the overall course of the disease is unfavourable in many affected individuals. Therefore, other therapeutic targets than dopaminergic and serotonergic neurotransmitters are being considered. Glutamatergic hypofunction, mediated mainly by NMDA receptor blockade, is suggested to be indirectly responsible for dopaminergic dysfunction in schizophrenia. Increased levels of kynurenic acid (KYN-A), an endogenous NMDA receptor antagonist, resulting from disturbed tryptophan/kynurenine metabolism can explain psychotic symptoms and cognitive deterioration. The role of the immune system in the production of KYN-A and therapeutic targets in the immune and glutamate systems are outlined. Therapeutic consequences are discussed. Glutamate modulators that particularly influence the NMDA co-transmitters glycine and serine, including inhibitors of glycine transporters, are described and initial clinical evidence is discussed. Another target of the glutamate system is the metabotropic mGlu2/3 receptor; Preliminary clinical results of a study with a mGlu2/3 receptor agonist in schizophrenia are mentioned.Keywords
This publication has 95 references indexed in Scilit:
- Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNature Medicine, 2007
- A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in SchizophreniaNeuropsychopharmacology, 2007
- Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trialSchizophrenia Research, 2007
- Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brainJournal of Neural Transmission, 2006
- Psychotropic Effects of COX-2 Inhibitors - A Possible New Approach for the Treatment of Psychiatric DisordersPharmacopsychiatry, 2004
- Prostaglandin-mediated control of rat brain kynurenic acid synthesis – opposite actions by COX-1 and COX-2 isoformsJournal of Neural Transmission, 2004
- Type 2 Metabotropic Glutamate (mGlu) Receptors Tonically Inhibit Transmitter Release in Rat Caudate Nucleus: In Vivo Studies with (2S,1′S,2′S,3′R)‐2‐(2′‐carboxy‐3′‐phenylcyclopropyl)glycine, a New Potent and Selective AntagonistEuropean Journal of Neuroscience, 1997
- The Nagging Question of the Function ofN-AcetylaspartylglutamateNeurobiology of Disease, 1997
- Kynurenine Disposition in Blood and Brain of Mice: Effects of Selective Inhibitors of Kynurenine Hydroxylase and of KynureninaseJournal of Neurochemistry, 1996
- Elevated plasma prostaglandin E2 levels in schizophreniaJournal of Neural Transmission, 1989